➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
Boehringer Ingelheim
Medtronic
Express Scripts
Colorcon

Last Updated: September 16, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LINAGLIPTIN

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Linagliptin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00309608 ↗ Efficacy and Safety of BI 1356 BS (Linagliptin) in Combination With Metformin in Patients With type2 Diabetes Completed Boehringer Ingelheim Phase 2 2006-04-01 The objective of the study is to test the efficacy, safety and tolerability of several doses of BI 1356 BS (1, 5, or 10 mg taken once daily) compared to placebo given for 12 weeks together with metformin in patients with type 2 diabetes mellitus who are not at goal with their HbA1c levels. In addition, there will be an unblinded treatment arm with glimepiride as add-on therapy to metformin for comparison. The influence of several factors (gender, age, weight, race, etc.) on the bioavailability and efficacy of BI 1356 BS will also be tested in this study.
NCT00328172 ↗ Efficacy and Safety of 3 Doses of BI1356 (Linagliptin) in Type 2 Diabetes Patients Completed Boehringer Ingelheim Phase 2 2006-05-01 The objective of the current study is to investigate the efficacy, safety and tolerability of several doses of BI 1356 BS (0.5, 2.5 and 5 mg daily) compared to placebo over 12 weeks of treatment in patients with Type 2 diabetes and insufficient glycemic control. In addition, there will be an open-label treatment arm with metformin for sensitivity measurement with this patient population. Population pharmacokinetics of BI 1356 BS will also be assessed in this study.
NCT00601250 ↗ Efficacy and Safety of B I1356 (Linagliptin) vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 Diabetes Completed Boehringer Ingelheim Phase 3 2008-01-01 The objective of the current study is to investigate the efficacy, safety and tolerability of BI 1356 (5 mg once daily) compared to placebo given for 24 weeks as add-on therapy to metformin in patients with type 2 diabetes mellitus with insufficient glycaemic control
NCT00602472 ↗ BI 1356 (Linagliptin) in Combination With Metformin and a Sulphonylurea in Type 2 Diabetes Completed Boehringer Ingelheim Phase 3 2008-02-01 The objective of the current study is to investigate the efficacy, safety and tolerability of BI 1356 (5 mg once daily) compared to placebo given for 24 weeks as add-on therapy to metformin in combination with a sulphonylurea in patients with type 2 diabetes mellitus with insufficient glycaemic control.
NCT00621140 ↗ Efficacy and Safety of BI 1356 (Linagliptin) Versus Placebo in Type 2 Diabetic Patients With Insufficient Glycemic Control Completed Boehringer Ingelheim Phase 3 2008-02-01 To investigate efficacy, safety and tolerability of BI 1356 versus placebo
NCT00641043 ↗ Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone Completed Boehringer Ingelheim Phase 3 2008-03-01 The objective of the current study is to investigate the efficacy, safety and tolerability of BI 1356 (Linagliptin) (5 mg / once daily) compared to placebo given for 24 weeks as initial combination therapy with pioglitazone 30 mg in patients with type 2 diabetes mellitus with insufficient glycaemic control.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Linagliptin

Condition Name

Condition Name for Linagliptin
Intervention Trials
Diabetes Mellitus, Type 2 51
Healthy 26
Type 2 Diabetes 11
Type 2 Diabetes Mellitus 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Linagliptin
Intervention Trials
Diabetes Mellitus, Type 2 76
Diabetes Mellitus 75
Renal Insufficiency 7
Insulin Resistance 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Linagliptin

Trials by Country

Trials by Country for Linagliptin
Location Trials
United States 388
Canada 86
Germany 36
Australia 27
Italy 23
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Linagliptin
Location Trials
Texas 25
Florida 23
California 22
Georgia 17
South Carolina 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Linagliptin

Clinical Trial Phase

Clinical Trial Phase for Linagliptin
Clinical Trial Phase Trials
Phase 4 33
Phase 3 44
Phase 2 8
[disabled in preview] 44
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Linagliptin
Clinical Trial Phase Trials
Completed 70
Recruiting 23
Not yet recruiting 13
[disabled in preview] 20
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Linagliptin

Sponsor Name

Sponsor Name for Linagliptin
Sponsor Trials
Boehringer Ingelheim 75
Eli Lilly and Company 36
Hospital Regional de Alta Especialidad del Bajio 5
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Linagliptin
Sponsor Trials
Industry 134
Other 78
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Baxter
Express Scripts
Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.